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Aims:To evaluate our outcomes of the adjustable continence balloons ProACT™ for
the treatment of male stress urinary incontinence after radical prostatectomy.
Methods: Between May 2007-August 2016 the ProACT™ was implanted in 143
patients without a history of radiotherapy. Endpoints were patient-reported changes in
pad counts and complications. Treatmentwas considered successful if no pad or just one
“security” pad per day sufficed, and improved if daily pad use was reduced by ≥50%.
Results: Incontinence before implantation was mild in 36 (25%), moderate in 57
(40%), and severe in 50 (35%) patients. Complications within 30 days were classified
by the Clavien-Dindo classification; eight (5.6%) grade I, three (2.1%) grade II, three
(2.1%) grade IIIb, and 129 (90.2%) patients had no complication. Revision was done
in 43 (30%) patients. The IPSS quality of life item improved significantly from 5.0
(IQR4.0-5.0) preoperative to 2.0 (IQR1.0-4.0) and 1.0 (IQR0.0-3.0) 6 and 12months
after implantation, respectively. After a median follow up of 56 months (range 28 to
79, n= 112), 72 (64%) patients were improved, including 51 (45%) patients were
successful. Daily pad use decreased from 3.0 to 1.0 (67% reduction). The median
outcome on the Patient Global Impression of Improvement scale was “much better,”
and 97 (87%) patients perceived improvement.
Conclusions: The minimally invasive ProACT™ device showed a clear beneficial
continence outcome in patients with stress urinary incontinence after radical
prostatectomy. The majority of the patients were satisfied and perceived
improvement ≥50% on daily pad use on the long term.
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1 | INTRODUCTION
Post-prostatectomy urinary incontinence (PPI) is a devastat-
ing complication after a radical prostatectomy (RP).1 In most
cases this concerns stress urinary incontinence (SUI) caused
by intrinsic sphincter deficiency.2 The prevalence of SUI after
is up to 60%, at varying times after the operation.3 Usually,
SUI has a great negative impact on the patients’ quality of
life.2,4 Several approved devices for the surgical treatment for
male SUI are available. One of these is the ProACT™ device
(Uromedica, Inc., MN) which consists of two periurethrally
placed volume-adjustable balloons.1 The volume of the
balloons can be adjusted in an outpatient setting to achieve the
optimal balance between voiding pressure and continence.1
Successful outcome after ProACT™ implantation has been
correlated with an increase in urethral resistance and
increased maximum urethral closure pressure.5,6
Several studies reported a significant reduction of daily pad
use and improvement on quality of life index scores with the use
of ProACT™. Some studies showed dry or daily pad use
improvement rates ranging from 60-92% limited to 12-24
months.1,7–9 Long term outcomes reported in the literature are
hardly available. Three studies with a mixed population of
patients with PPI and post transurethral resection of the prostate
incontinencewitha followup ranging from56-58months showed
a 50-66% overall dry rate, defined as “no pad or one security
pad,”10,11 or a 4.5% overall dry rate, defined as “no pads.”12
Quality of life is an important outcome domain in the
treatment of urinary incontinence.13Multiple-question condition-
specific quality of life instruments give access to many
components of the condition, but some are extensive and
minimally suitable in the standard clinical setting.13–15 The
Patient Global Impression of Improvement (PGI-I) scale is a
global index thatprovidesanoverall response toan intervention.13
It is a simple, easy-to-use and easy to interpret tool in clinical
practice and research settings.13–15 The PGI-I scale has been used
and/or has been validated for women with SUI,13 women with
urogenital prolapse,14 men with lower urinary tract symptoms
secondary to benign prostatic hyperplasia,15 and patients with
non-urological diseases.16
We have been using the ProACT™ device for the
treatment of male SUI after RP at our department Urology
since May 2007. The aim of this study is to evaluate our
results in terms of success, changes in pads use, complications
and patient-reported estimates of improvement assessed with
the PGI-I scale.
2 | PATIENTS AND METHODS
2.1 | Study population
We included patients with SUI after RP who had the
ProACT™ device implanted between May 2007 and
August 2016 after conservative treatment with pelvic floor
exercises for 1 year had failed. In all patients the possibility of
adjustable continence balloons, male sling, and artificial
sphincter were discussed. Patients with an artificial urinary
sphincter (AUS) or male sling in situ and those with a history
of adjuvant radiotherapy after RP were excluded. Severe SUI
and a history of failed and removed urinary incontinence
devices (AUS, male sling, or ProACT™) were not exclusion
criteria. All included patients underwent a cystoscopy (to
assess the presence of a stricture) and an urodynamic study.
2.2 | Intervention
Initially, the ProACT™ device was implanted percutaneously
with the use of a rigid 19F cystoscope and fluoroscopy in the
anterior posterior direction. After April 2014 a flexible
cystoscope was used. The flexible cystoscope provides
retrospective intravesical examination during implantation
and the use of it may decrease the amount of bladder neck
perforations. Furthermore, a flexible cystoscope causes less
friction in the bladder neck than a rigid cystoscope and results in
less chance of increasedSUI just after placement of the balloons.
Two separate titanium ports are placed in the scrotum and
connected to each of the balloons, respectively, via a tube. All
procedures were performed by the same surgeon (BB) with the
patient in lithotomy position mostly under general anesthesia,
otherwise under spinal anesthesia. Perioperative intravenous
antibiotic prophylaxis consisting of cefazolin andmetronidazole
was given. In most cases patients were discharged from the
hospital on the day of surgery after removal of the transurethral
catheter and a successful voiding trial. If the bladder neck was
perforated intraoperatively the balloon was still placed
ipsilaterally of the perforation but as a rule more laterally than
without a perforation. In these patients, the transurethral catheter
was removed at day 5 or 7 and oral antibiotics were started at
approximately the removal time.After the implantation, patients
visited the outpatient clinic every 3-4 weeks. Balloon volume
was adjusted withmaximal 1 mL per balloon per visit by needle
puncture of the subcutaneous port sited in the scrotum. This was
done by a specialized nurse or by the surgeon until continence
was achieved.
2.3 | Design
After obtaining approval by the local ethics committee (MEC-
2017-05) all eligible patients were sent an information letter
and a three-item questionnaire with a return envelope:
1. The dichotomous question: “Would you recommend
ProACT™ to someone else?” to be answered by yes or no.
2. The PGI-I scale: check the number that describes how your
condition is now compared to before the ProACT™
implantation: 1. “verymuch better,” 2. “much better,” 3. “a
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little better,” 4. “no change,” 5. “a little worse,” 6. “much
worse,” 7. “very much worse.”
3. The open-ended question: How many pads do you use
daily?
Other relevant data were retrospectively retrieved from
the individual patients’ medical charts. Preoperative evalua-
tion included medical history, anamnestic pad count, voiding
diary, American Society of Anesthesiologists (ASA) classes,
and International Prostate Symptom Score (IPSS). The
severity of urinary incontinence was classified by the
anamnestic pad use per day and ranked as mild (one or two
pads), moderate (three or four pads), or severe (5 or more pads
or use of condom catheter). Postoperative evaluation included
anamnestic pad count, IPSS, and complications. Complica-
tions within 30 days postoperative were graded using the
Clavien-Dindo Classification of Surgical Complications.17
Failure of the intervention was defined as explantation with or
without revision of the ProACT™ device, or as an additional
surgical procedure needed because of persistent incontinence
(eg, onabotulinumtoxin-A injected in the bladder wall, sacral
neuromodulation, bulking agents, male sling, AUS).
Postoperative continence was assessed according to
changes in pad counts. The outcome of the treatment was
defined as “successful” when the patient was dry (no pad or a
single “security pad” per day); as “improved” when ≥50%
reduction in daily pad use against preoperative use was
reported; and as “little/no improvement” when <50%
reduction in daily pad use against preoperative use was
obtained. The PGI-I question served to evaluate a patient's
perception of improvement on his condition. A lower score on
the 7-point scale corresponds with a better condition than
before ProACT™ implantation.
2.4 | Statistical analysis
Statistical analyses were performed using SPSS version
21.0 (IBM Corp., Armonk, NY). A two-sided P-value
<0.05 was considered statistically significant. Descriptive
statistics are presented as percentages for qualitative
variables and median and interquartile range (IQR) for
quantitative variables. The Wilcoxon signed-rank test was
used to compare preoperative and postoperative quantitative
variables. A student-t-test was used to compare change in
pad use and outcome on the PGI-I scale. Time to ProACT™
failure is distributed in a Kaplan-Meier curve. A binary
multivariate logistic regression analysis was conducted
using the backward method. The parameters (age, BMI, pre-
operative use of >5 pads per day, time between
prostatectomy and implantation of ProACT™, and compli-
cations) with P< 0.05 on univariate analysis were consid-
ered in building the model to investigate the association
between these variables and a non-successful outcome.
3 | RESULTS
A total of 143 out of 150 patients were included; the median
follow up period was 46.0 (IQR 21.0–76.0) months. Seven
patients with a sling or AUS in situ were excluded. Patient
characteristics are shown in Table 1. The median time
between prostatectomy and ProACT™ implantation was
37.0 months (IQR 20.0-87.0 months). Twenty-one (14.7%)
patients had undergone prior anti-incontinence surgery with
bulking agents, AUS, urethral sling, urethrotomy, and/or
ProACT™ in various hospitals. At the time the question-
naires were sent 11 patients were deceased. Overall, the
median preoperative anamnestic pad use per day was 3.5
(IQR 2.0-5.0, n= 143). Urinary incontinence was classified
TABLE 1 Patient characteristics of the study population presented as
number (%) or median (interquartile range)
Characteristics, n= 143a
Age, years (IQR) 69.0 (66.0-73.0)
Weight, kg (IQR) 83.0 (78.0-89.0) (n= 142)
BMI, kg/m2 (IQR) 26.1 (24.1-28.1) (n= 142)
Type of prostatectomy
-Retropubic radical prostatectomy
-Laparoscopic radical prostatectomy
-Robot-assisted radical prostatectomy
65 (45.5)
33 (23.0)
45 (31.5)
Previous urological surger
-Urethrotomy
-Male sling
-AUS
-Bulking agents
-AUS and urethrotomy
-Male sling and ProACT™ in
different clinic
9 (6.3)
2 (1.4)
5 (3.5)
3 (2.1)
1 (0.7)
1 (0.7)
Incontinence severity before
-mild: 1-2 pads/day
-moderate: 3-4 pads/day
-severe: 5 or more pads/day
36 (25.2)
57 (39.8)
50 (35.0)
ASA score
-I
-II
-III
27 (18.9)
95 (66.4)
21 (14.7)
Type of anesthesia
-Spinal
-General
18 (12.6)
125 (87.4)
Operating time, minutes (IQR) 69.0
(60.0-77.0)
(n= 123)
Number of adjustments, n (IQR) 4.0
(2.0-6.0)
(n= 139)
Volume left balloon, mL (IQR)
Volume right balloon, mL (IQR)
4.5 (2.5-7.0)
4.5 (2.5-7.0)
(n= 134)
Died
-Reason unknown, after follow up
-Malignancy
-Multi organ failure
-Suicide
5
4
1
1
a Unless stated otherwise.
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as mild in 36 (25.2%), moderate in 57 (39.8%), and severe in
50 (35.0%) patients.
3.1 | Continence outcome
After implantation and a median of four balloon volume
adjustments daily pad usage had decreased significantly
from a median of 3.5 (IQR 2.0-5.0) pads per day
preoperatively to a median of 1.0 (IQR 0.0-2.0) pads per
day at 6 months and 0.0 (IQR 0.0-2.0) pads per day at 1 year
(Table 2). Six months after implantation 72.9% (97/133)
patients had ≥50% reduction in daily pad use against
preoperative, including 47.4% (63/133) who had become
dry (no pad or one security pad per day). After 1 year 50.6%
(48/95) patients were dry (no pad or one security pad per
day) of the 77.9% (74/95) patients whose daily pad use was
reduced with ≥50%. The score on the IPSS quality of life
item (IPSS-QOL) had improved significantly from 5.0 (IQR
4.0-5.0) preoperative to 2.0 (IQR 1.0-4.0) 6 months after
implantation and 1.0 (IQR 0.0-3.0) 12 months after
implantation (Table 2).
3.2 | Questionnaire
The questionnaires were sent to 132 patients with a response
rate of 120 (90.9%). The median time between the
implantation of ProACT™ and the questionnaire was 59.0
(IQR 29.0-87.0) months. One hundred and six (88.3%)
patients would recommend the ProACT™ to someone else,
eight (6.7%) not, and six (5.0%) did not answer this question.
In eight (6.7%) patients who responded on the questionnaire,
the ProACT™ has been removed; in three patients an AUS
was implanted; in two patients a male sling was implanted;
two patients accepted the incontinence; and one patient was
on the waiting list for the ProACT™. One hundred and twelve
(93.3%) patients had the ProACT™ in situ and 32 (28.6%)
responders had one or more ProACT™ revisions. The daily
pad use of the 112 responders with ProACT™ in situ
was significantly reduced from 3.0 (IQR 2.0-4.9) to 1.0
(IQR 0.0-2.9) pads per day after a median follow up of 56.0
(IQR 27.5-79.0) months (P< 0.001, Table 2). This corre-
sponds with a 66.7% decrease in pad use. The median
outcome on the PGI-I scale in the patients with the device in
situ was 2.0 (IQR 1.0-2.0, n= 111). Ninety-seven (87.4%)
patients reported improvement; 14 (12.6%) no difference or
deterioration. The mean difference in pad use before and after
the implantation was significantly different in those two
groups (P= 0.03), namely in the group with improvement on
the PGI-I scale mean decrease of 2.5 pad per day (mean pad
use pre-operative 3.7) and in the group with no difference or
deterioration on the PGI-I scale 0.0 pad per day (mean pad use
pre-operative 5.3).
3.3 | Intraoperative complications
Seventeen (11.9%) intraoperative perforations of the urethra
occurred. In two cases, there was minimal perforation and
patients received antibiotics and the transurethral catheter was
removed the same day. The other 15 patients were treated
with a transurethral catheter from 5 to 7 days.
TABLE 2 Outcome on daily pad usage, continence, IPSS total, and IPSS QOL, presented as number (%) or median (interquartile range)
Preoperative
6 months after
implantation
1 year after
implantation
Median 56 (28-79) months
follow-up
n= 143 n= 133 n= 95 n= 112
Anamnestic pads/day, median (IQR)
P-value (difference from
preoperative)a
3.5 (2.0-5.0)
-
1.0 (0.0-2.0)
<0.001
0.0 (0.0-2.0)
<0.001
1.0 (0.0-2.9)
<0.001
n= 133 n= 95 n= 112
Postoperative outcome on continence
-Successful, n (%)
-≥50-99% reduction in daily pad
use, n (%)
-Little or no improvement, n (%)
63 (47)
34 (26)
36 (27)
48 (51)
26 (27)
21 (22)
51 (45)
21 (19)
40 (36)
n= 78 n= 107 n= 65
IPSS total, median (IQR)
P-value (difference from preoperative)a
8.5 (4.8-14.0)
-
6.0 (3.0-10.0)
0.38
5.0 (2.0-11.0)
0.08
n= 81 n= 106 n= 66
IPSS QOL, median (IQR) 5.0 (4.0-5.0) 2.0 (1.0-4.0) 1.0 (0.0-3.0)
P-value (difference from preoperative)a - <0.001 <0.001
aThe Wilcoxon signed-rank test was used to compare preoperative and postoperative results.
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3.4 | Post-operative complications
In Table 3 the short-term (<30 days) post-operative
complications and management are summarized. By the
Clavien-Dindo classification, three (2.1%) complications
were grade IIIb. Two (1.4%) patients had post-operative
pain. A total of 129 (90.2%) patients had no complication. On
the long term (>30 days), 78 (55.7%) patients had no
complication. There were 79 (55.2%) patients without failure
of the ProACT™. One or more revisions had been done in 43
(30.1%) patients, mostly because of an unilateral balloon
defect (Table 4). Two patients received an AUS after one
ProACT™ revision and one patient after two ProACT™
revisions. After balloon failure nine (6.3%) patients accepted
the situation. An additional surgery was given to six (4.2%)
patients (eg, onabotulinumtoxin-A injected in the bladder
wall, sacral neuromodulation, bulking agents). Six (4.2%)
patients with failure of the ProACT™ received a different
device after removing the balloons (four patients an AUS and
two patients a male sling). The failure-free survival after
ProACT™ implantation is shown in a Kaplan-Meier curve
(Figure 1).
After a median follow up of 56.0 months univariate
logistic analysis showed, intraoperative perforation (OR
13.89, P= 0.012), short (OR 8.00, P= 0.001) and long term
(OR 6.83, P< 0.001) complication, and the number of
adjustments of the balloons (OR 1.47, P< 0.001) were
significant parameters. Whereas age (P= 0.431), BMI
(P= 0.942), time between prostatectomy and implantation
of ProACT™ (P= 0.889), and pre-operative >5 reported
pads per day (P= 0.183) were not significantly parameters
and were not considered in building the model. Multivariate
logistic regression analysis showed short term complications
(OR 8.41, P= 0.004) and the number of adjustments of the
balloons (OR 1.46, P= 0.002) were both independently
associated with a non-successful outcome.
4 | DISCUSSION
The aim of this study was to evaluate our results with the
implantation of the ProACT™ device, with a focus on the
patients’ perception of improvement after implantation.
After a median follow up of 56 months, 112 patients with
ProACT™ in situ reported a 45% dry rate and a 64%
improvement of continence rate. The dry rate in our study
is within the range (4.5-66%) reported in studies with
comparable follow up.10–12 Venturino et al12 defined dry
as “no pads” versus “no or one security pad” in our study
and the studies of Kjaer et al10 and Rouprêt et al.11 Further,
the decrease in daily pad use (67%) in our study is more
beneficial than reported in other studies with comparable
follow up, ranging from 34% to 65%.10–12 However,
patient baseline characteristics were not comparable with
those in other studies.10–12 Our study population were men
with SUI after RP without a history of adjuvant
radiotherapy and we did not include patients with SUI
after a transurethral resection of the prostate. A recently
TABLE 3 Post-operative complications, <30 days, presented as number, and graded using the Clavien-Dindo classification
n= 143 Cause Management
No complication 129
Grade I 8 7 acute urinary retention
1 intraoperative perforation and scrotal hematoma
Catheter for a week and prophylactic antibiotics around removing
the catheter
Catheter for a week and antibiotics
Grade II 3 2 scrotal hematoma and pain
1 infection
Oral pain medication
Antibiotics
Grade IIIb 3 1 urethral perforation and hematuria
1 infection and intraoperative perforation
1 dislocation and pain
Removed under local anesthetics and new balloons were
implanted 2-4 months after removal
TABLE 4 Reasons of ProACT™ reinterventions, presented in numbers (%)
ProACT™ reinterventions First redo Second redo Third redo Fourth redo
Defect of the balloon(s) 22 (15.4) 8 (5.6) 1 (0.7)
Infection 5 (3.5) 1 (0.7) 1 (0.7) 1 (0.7)
Bladder neck perforation 2 (1.4) 2 (1.4) 1 (0.7)
Erosion 2 (1.4) 1 (0.7)
Persistent incontinence 8 (5.6)
Migration/dislocation 4 (2.8) 2 (1.4)
Total 43 (30.1) 13 (9.1) 3 (2.1) 2 (1.4)
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performed systematic review comparing surgical devices
for SUI after RP reported an average dry or one safety pad
rates of 66%, 48%, and 64% for AUS, male sling, and
ProACT™, respectively.4 Therefore, balloon compression
devices like ProACT™ and AUS seem to have similar
superior symptom related outcome compared to the male
sling, but the AUS was associated with the highest
complication rate.4
In our study population, revision of ProACT™ was done
in 43 (30%) patients. This revision rate is within the range of
the literature, ranging from 13% to 73%.1,10–12 A significant
difference was found in the mean number of balloon
adjustments between the failure and the failure-free group,
5.4 versus 3.0 adjustments, respectively. This implicates that
more tension on the balloon wall results in a higher chance of
balloon failure. Another hypothesis could be that patients will
become more active with better continence, which gives
potentially more traction on the scrotally placed tubes
resulting in friction between the balloons and ramus inferior
of the pubic bone.
Almost 90% of the patients were satisfied with this
treatment, which can be concluded from the scores on the
PGI-I scale and the recommendations to others. The median
outcome on the PGI-I scale after a median follow up of
56 months was “much better” and 87% perceived improve-
ment. Besides, the change in pad use after the implantation
was significantly different between the group with improve-
ment and the group with no difference or deterioration on the
PGI-I scale. Experiencing improvement seems to be
proportional to improvement on the change in pad use. The
PGI-I may be a valuable tool to evaluate a man's overall
appraisal of his condition and his response to surgical
treatment for SUI in clinical practice and studies. Since many
patients are coming from regions outside the direct vicinity of
our hospital, they informed themselves via relatives and/or
internet on the possibility of the adjustable continence
balloons and asked for referral to our hospital. Consequently,
almost all patients choose to be implanted with these balloons
initially and not with the alternative options. This could give
some bias on the satisfaction. Another possible bias could be
the time between the question and the operation. The patient
could forget how the situation was precisely before the
operation. The validity of the PGI-I in men with SUI has not
yet been established. However, a good construct validity of
the PGI-I has been established in women with SUI and in men
with lower urinary tract symptoms secondary to benign
prostatic condition.13,15
In contrast to Utomo et al6 severe pre-operative urinary
incontinence (>5 pads per day) and longer duration of PPI in
the present study were not independently associated with non-
successful treatment outcome. This discrepancy is possibly
explained by our longer median follow up (56 vs 9 months)
and larger number of patients (112 vs 49). Short term
complication and the number of balloon adjustments were
significantly associated with a non-successful outcome. The
intraoperative perforations were included in the short term
complications. The majority of the short term complications
were due to an intraoperative perforation. A non-successful
outcome after a intraoperative perforation might be the result
of the more lateral position of the balloon at the site of the
perforation and the necessity for more balloon adjustments to
achieve continence. It might be concluded not to place the
balloon at the site of perforation in the same surgical session
but this necessitates an extra operation and results in financial
damage due to loss of the balloon.
Limitations of our study are inherent to the retrospective
design. Moreover, the individual learning curve of the
surgeon involved might have affected the results. As
described by Hübner and Schlarp8 the treatment outcome
can be improved with the learning curve.
Strengths of our study are the large number of patients and
the relatively long follow up period. In various cohort and
feasibility studies the follow up period ranged from 51 to
58 months and the number of patients from 22 to 128.10–12
The prospectively sent questionnaire provided patient-
determined estimates of their outcome and changes in daily
pad use, which can be considered a strength.
The results suggest that ProACT™ is the minimal
invasive first line surgical treatment for PPI (without
stratification of severity of PPI) before opting for a more
invasive treatment, such as male sling or AUS. The balloons
can be adjusted in the outpatient clinic, in case of failure the
device can be easily removed in the outpatient clinic and
another treatment or revision can be considered. Further
research is needed, however, to determine outcome pre-
dictors. A possible outcome predictor could be the anatomy of
the bladder neck post-prostatecomy.
FIGURE 1 Failure free survival after implantation of ProACT™
distributed in a Kaplan-Meier curve
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5 | CONCLUSION
Our results demonstrate improvement of the continence rate
and satisfaction in the majority of patients with SUI after RP
without a history of radiotherapy after implantation of
adjustable continence balloons. The revision rate should be
discussed preoperatively with patients. Future clinical evalua-
tion is, however, necessary to determine outcome predictors.
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